TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
94 hedge funds and large institutions have $74.8M invested in TCR2 Therapeutics Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 36 reducing their positions, and 41 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less ownership
Funds ownership: 76.37% → 70.37% (-6%)
23% less funds holding
Funds holding: 122 → 94 (-28)
33% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 36
45% less capital invested
Capital invested by funds: $136M → $74.8M (-$61.2M)
66% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 41
90% less call options, than puts
Call options by funds: $7K | Put options by funds: $69K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.44M |
| 2 |
Renaissance Technologies
New York
|
+$1.73M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.46M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.13M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$781K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.23M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.89M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3.19M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.63M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$1.01M |
TCRR Hedge Fund Activity: Q1 2022 in Review
94 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q1 2022, worth a combined $74.8M — down 45% from $136M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of TCRR and 14 opened new positions — a net loss of 27 holders — while 36 trimmed existing stakes and 24 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $9.44M. The largest seller was Millennium Management, cutting an estimated $4.23M.
- 94 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q1 2022, down from 122 in Q4 2021.
- Funds reported $74.8M of TCR2 Therapeutics Inc. Common Stock stock for Q1 2022, down 45% quarter-over-quarter.
- 14 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q1 2022 and 41 closed out, a net change of -27 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q1 2022 was Tang Capital Management, an estimated $9.44M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q1 2022 was Millennium Management, an estimated $4.23M sold.
Based on aggregated 13F filings for Q1 2022.